fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

FDA approves pediatric indication extension for Palforzia (arachis hypogaea) oral immunotherapy for treatment of peanut allergy – Stallergenes Greer

Written by | 10 Sep 2024

Stallergenes Greer, a leading global healthcare company specialising in allergen immunotherapy, announced that the FDA has approved Palforzia [Peanut (Arachis hypogaea) Allergen Powder-dnfp], for the treatment of toddlers… read more.

Stallergenes Greer acquires Palforzia peanut allergy treatment business from Nestle

Written by | 9 Sep 2023

Nestlé announced that is has divested Palforzia, its peanut allergy treatment business, to Stallergenes Greer, a biopharmaceutical company which specializes in the diagnosis and treatment of allergies. The… read more.

National Institute of Health and Care Excellence (NICE) (UK) recommends Palforzia for treating peanut allergy in children – Aimmune/Nestle

Written by | 7 Feb 2022

NICE (UK)-Palforzia from Aimmune/Nestle is recommended, within its marketing authorisation, as an option for treating peanut allergy in children aged 4 to 17. It can be continued in… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.